Renalytix Share Discussion Threads

[homebrewruss] 28/10/2020 07:09

EKF Diagnostics Holdings PLC EKF & Kantaro partner to market antibody testing

[wan] 28/10/2020 04:26

Under the circumstances, I thought the presentation was as good as it could have been (quarterly Nasdaq reporting will apparently change the format somewhat).

The Q&A was excellent and is worth investors making the effort to listen to, with strategic partnerships (they are apparently getting a lot of inbound!), in-licensing/other opportunities, Kantaro, the 'platform' aspect/potential of the KidneyIntelx technology, and eventually providing more colour on UK and European entry all getting some coverage.

James (the CEO) in particular comes across as very focused and determined, and clearly very knowledgeable indeed.

We have a very experienced management team with huge collective knowledge addressing a huge unmet medical need. Given the progress to date, the early indications and commentary are very encouraging!

[mr roper] 27/10/2020 17:37

Quite enjoyed the call actually. Q A was good. Next few months should see a decent amount of newsflow

[faz] 27/10/2020 17:23

James you just got your answer. THey are constricted by Nasdaq to a no presentation format and script reading. Going forward they will be reporting quarterly and there may be presentations (presumably when not formally reporting).

[james188] 27/10/2020 16:57

The live presentation is pretty hard going, as the CEO is simply reading straight from a prepared script - so it comes over as very wooden. Ditto the CFO presentation. No graphics at all. The other attendees frankly look bored. Quite a contrast to the EKF presentation on the same InvestorMeetCompany a few weeks ago, which showed how it should be done. I cannot stay for the Q&A, but hopefully it will be more informative than the core presentation.

The company has a promising business, but it has some way to go in the way that it communicates.

[mr roper] 27/10/2020 09:30

Really? They have an excellent product that they are trying to monetise through a variety of streams. Pretty straightforward.
The Covid test jv for me is a sideshow.

[mr roper] 27/10/2020 09:13

Solid set of results. Next few quarters should hopefully start to show the revenue build up. I think we are going to quarterly reporting from now as well in line with Nasdaq so hopefully should be a steady newsflow til the next update.

There’s a lot going on here, pretty exciting times.

[74tom] 27/10/2020 09:03

No doubting that they've achieved a significant amount over the last 12 months, but the future is what we now care about! Let's hope the strong newsflow that characterised the first half of the year now resumes :)

[pugugly] 27/10/2020 07:54

UK retails investor presentation

RenalytixAI will be hosting a live online presentation open to all investors at 12.30 p.m. (EDT) / 4.30 p.m. (BST) on Tuesday, October 27 2020. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on the recent developments and additionally providing an update on the business, which will be provided by both James McCullough, CEO and O. James Sterling, CFO.



The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet Renalytix AI plc via the following link:

[wan] 27/10/2020 07:45

The Results provide encouraging reading with excellent progress being made. There's not much doubt that the government policy change favouring innovation, particularly in the kidney disease field, will continue to provide a very supportive backdrop, drive further corporate activity and transformation of the kidney disease sector.

Further strategic collaborations and FDA progress, especially with regard to the new proposed CMS rule which could help shorten the time to insurance coverage for some 12 million Americans, could provide for share price catalysts. In my view, there is good reason to be hopeful on Renalytix achieving all of these!

[nimbo1] 27/10/2020 07:44

All good stuff - but the only thing I really care about is testing volumes done since Test available and can’t see that mentioned. Also how quickly they expect to scale.

[cambridgedon] 26/10/2020 15:28

Just got A J Bell email. Decision due by midnight tonight!
I've signed up for some.
CD

[faz] 26/10/2020 14:57

Me too toffeeman- not good for folk who don;t get PC access and time during the day!

[toffeeman] 26/10/2020 14:43

AJ Bell just emailed me to apply for VericiDX - I have subscribed for a few.

[wan] 26/10/2020 14:29

Antibody tests are not the hottest news/test at present. Hence the somewhat muted response, and that Bio-techne are "prepared" to produce up to 10 million tests per month and ready to support further expansion (when/if required!).

In my view, it's currently far more about have we got Covid-19 or not, and not have I had it! The tests will undoubtedly be useful in terms of understanding immune response etc (which the RUO tests already does), but I am no longer envisaging the type of volumes/opportunity first envisaged by Bio-techne. But I could be wrong!

Perhaps for healthcare workers/front line staff it might be a useful test to take (especially if you think you have had it).

Let's see what Renalytix/Kantaro have to say on the matter.

[74tom] 26/10/2020 14:20

50/50 for me. HL have sorted the corporate action out very well & I've just applied for some open offer shares. However, I haven't heard anything from Barclays and clearly they are going to miss the boat. A shame that all brokers couldn't work in unison on something like this.

Very good news on Kantaro though, that at least opens up quite a few markets...

[faz] 26/10/2020 14:05

cambridgedon- same here (AJ Bell) . Messaged them over the weekend. Kantaro news is good!

[mginvestor] 26/10/2020 13:06

Renalytix just tweeted this out:



NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX /NASDAQ: RNLX), and partner Bio-Techne Corporation (NASDAQ: TECH) have received CE marking for COVID-SeroKlir and COVID-SeroIndex, Kantaro's quantitative SARS-CoV-2 IgG antibody test kits. Both kits are available immediately and can be used by any authorized clinical testing laboratory in the European Union without the need for proprietary equipment. Approved as in vitro diagnostics (IVD), COVID-SeroKlir is configured to be most useful in a clinical setting, while the COVID-SeroIndex configuration is expected to be used for research purposes or vaccine development.

The COVID-SeroKlir and COVID-SeroIndex quantitative antibody test kits detect the presence or absence of COVID-19 antibodies and measures the titer (level) of antibodies a person has produced. The tests utilize not one but two virus antigens: the full-length spike protein and its receptor-binding domain (RBD), which are correlated with antibody neutralization, as described in a recent paper published in Nature Medicine. The COVID-SeroKlir quantitative antibody test kit has demonstrated 97.8% sensitivity and 99.6% specificity.

The underlying technology in Kantaro's test kits was developed by Mount Sinai at the height of the COVID-19 pandemic in New York City. It was used recently in a published study by researchers at the Icahn School of Medicine at Mount Sinai, which found most people with COVID-19 mount a robust antibody response stable for at least three months, which subsequent studies have extended out to six months. To date, the Mount Sinai technology has been used on over 75,000 patients, representing a highly diverse population.

"Confirming past COVID-19 infection with specific numerical values helps patients to take control of their health and provides vital information for the clinician trying to understand the long-term impact of COVID-19 on other health issues such as cardiac, lung and kidney health," said Sara Barrington, Kantaro's chief commercial officer. "Additionally, knowing specific levels of neutralizing antibodies a person has produced is an important part of understanding immunity and supporting long-term public health strategies."

"COVID-SeroKlir and COVID-SeroIndex receiving CE mark approval is an important step in the global commercialization plan for these best-in-class quantitative antibody test kits," said Chuck Kummeth, Bio-Techne's president and chief executive officer. "We are prepared to produce up to 10 million tests per month and ready to support any further rapid expansion."

[cambridgedon] 26/10/2020 12:56

CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex Quantitative Antibody Test Kits.
Just seen this announcement via the FT website?
CD
PS Just spoke with Link re; the missing application form for Verici. They are on the case.

[busterdog2] 26/10/2020 12:24

No sign of the application form with the Halifax either.

[toffeeman] 26/10/2020 08:10

Yep - also with AJB

[cambridgedon] 26/10/2020 08:04

Verici.
Still nothing from A J Bell. I have asked them when the application form for the restricted offer will be available. No response! Worrying, since the deadline for applications is tomorrow. Anyone else having problems?
CD

[donmac101] 23/10/2020 18:46

Thanks for the heads up not.
Got a few today on hargreaves didnt notice the message on my account as i use the app.appreciate all the help cheers.

[donmac101] 23/10/2020 07:59

Am i correct to say the verici application form is in the post.or is it online somewhere?

[owlbaby] 22/10/2020 10:25

NVTA mcap $7.8bn Turnover 200m, Personalis mcap 900m t/o 65m, Twist 3.8bn t/o 54m


hot space indeed